Trial Profile
Pexacerfont for Reduction of Stress-Induced Food Craving and Eating in Humans
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Pexacerfont (Primary)
- Indications Generalised anxiety disorder; Irritable bowel syndrome; Major depressive disorder
- Focus Therapeutic Use
- 19 Dec 2017 New trial record